Evidence map›Paper›PMID 42278263›Full record

SynthesisInternational journal of molecular sciences2026

TP53 Mutations Unfavorably Impact the Outcomes of Myelofibrosis Patients with or Without Hematopoietic Stem Cell Transplantation: A Single-Center Study and Meta-Analysis.

Filippo Frioni, Sabrina Giammarco, Sara Ceglie, Silvia Betti, Francesco Ramundo, John Marra, Monica Rossi, Federica Fosso, Gessica Minnella, Elisabetta Metafuni and 6 more

Abstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Filippo FrioniSection of Hematology, Department of Laboratory and Hematological Sciences, Catholic University, 00168 Rome, Italy.
Sabrina GiammarcoFondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.ORCID 0000-0002-1382-5496
Sara CeglieFondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
Silvia BettiFondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
Francesco RamundoSection of Hematology, Department of Laboratory and Hematological Sciences, Catholic University, 00168 Rome, Italy.
John MarraSection of Hematology, Department of Laboratory and Hematological Sciences, Catholic University, 00168 Rome, Italy.
Monica RossiFondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
Federica FossoFondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
Gessica MinnellaFondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
Elisabetta MetafuniFondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.ORCID 0000-0002-4780-1273
Federica SoràSection of Hematology, Department of Laboratory and Hematological Sciences, Catholic University, 00168 Rome, Italy.
Andrea BacigalupoFondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.
Simona SicaSection of Hematology, Department of Laboratory and Hematological Sciences, Catholic University, 00168 Rome, Italy.ORCID 0000-0003-2426-3465
Elena RossiSection of Hematology, Department of Laboratory and Hematological Sciences, Catholic University, 00168 Rome, Italy.
Valerio De StefanoSection of Hematology, Department of Laboratory and Hematological Sciences, Catholic University, 00168 Rome, Italy.ORCID 0000-0002-5178-5827
Patrizia ChiusoloSection of Hematology, Department of Laboratory and Hematological Sciences, Catholic University, 00168 Rome, Italy.ORCID 0000-0002-1355-1587

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TP53 mutation is known to be a poor prognostic factor in many hematologic malignancies, but it is not included in any Myelofibrosis-specific prognostic score. Recently, studies have shown that TP53 mutation may negatively impact the outcomes of patients with Myelofibrosis, including those undergoing hematopoietic stem cell transplantation. In this study, we aimed to analyze the impact of TP53 mutation on the overall survival and leukemia-free survival of patients with chronic-phase Myelofibrosis, regardless of whether they had undergone transplantation. A total of 250 patients were included in the study, of whom 9 (3.2%) harbored a TP53 mutation, including six (3.2%) among non-HSCT patients and three (3.1%) among HSCT patients. In both groups, the presence of TP53 mutation correlated with shorter overall survival, while in non-HSCT patients, it also correlated with lower leukemia-free survival. Moreover, we provide a meta-analysis on the role of TP53 mutation in patients with chronic-phase Myelofibrosis, confirming its negative prognostic impact on overall survival.

Indexed as

Hematopoietic Stem Cell TransplantationMutationPrimary MyelofibrosisTumor Suppressor Protein p53AdultAgedFemaleHumansMaleMiddle AgedPrognosisTreatment OutcomeTP53 protein, humanTumor Suppressor Protein p53hematopoietic stem cell transplantationMyelofibrosisTP53 mutation

Identifiers

PMID42278263
PMCPMC13256192

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.